WebDoctor Encyclopedia

Liver, bile ducts & pancreas

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA)

Combined hepatocellular-cholangiocarcinoma is a rare liver cancer containing both liver-cell and bile-duct-cell cancer in one tumour. It shares risk factors with liver cancer, is often found only after surgery, and has an outlook similar to bile duct cancer.

Medically reviewed Last reviewed October 21, 2026

What is combined hepatocellular-cholangiocarcinoma?

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer that contains two kinds of cancer cells in the same tumour. Some cells resemble liver cells (hepatocytes), as in hepatocellular carcinoma (HCC). Others resemble bile duct cells (cholangiocytes), as in intrahepatic cholangiocarcinoma (iCCA).

These tumours have been described for over a century, but they are now recognised more often. An international consensus in 2018 agreed on a common name and definition, so that doctors around the world can study and treat them in the same way (Brunt et al., 2018). The diagnosis is made mainly from the appearance of the tumour under the microscope, with special stains used for support.

cHCC-CCA shares many risk factors with HCC, such as cirrhosis and chronic hepatitis B or C. On average it carries a poorer outlook than HCC, much like intrahepatic cholangiocarcinoma (Beaufrère, Calderaro and Paradis, 2021).

Surgery offers the best chance of cure. For cancer that cannot be removed, doctors use chemotherapy, targeted drugs or immunotherapy, but there is still no agreed standard treatment.

1. Key facts at a glance

Feature Details
Type of cancer Primary liver cancer with both liver-cell and bile-duct-cell features
How common A small minority of primary liver cancers
Typical age Usually 55-75
Sex More common in men
Main risk factors Cirrhosis, hepatitis B or C, alcohol, fatty liver disease
Tumour markers AFP, CA 19-9 or both may be raised
Common sites of spread Lymph nodes, elsewhere in the liver, lungs, bone, peritoneum
Main treatment Liver resection with lymph node removal; systemic therapy for advanced disease
Outlook Worse than HCC; similar to intrahepatic cholangiocarcinoma

2. How cHCC-CCA compares with other liver cancers

Feature Hepatocellular carcinoma Combined HCC-CCA Intrahepatic cholangiocarcinoma
Cell type Liver cells Both Bile duct cells
Cirrhosis Very common Common Less common
Raised AFP Often Sometimes Rarely
Raised CA 19-9 Rarely Sometimes Often
Lymph node spread Uncommon Common Common
Liver transplant Standard for selected patients Controversial Only in research settings

3. Causes and risk factors

Risk factor Notes
Cirrhosis Scarring of the liver from any cause
Chronic hepatitis B A major risk factor, especially in Asia
Chronic hepatitis C A major risk factor in Europe and North America
Alcohol Long-term heavy drinking
Metabolic dysfunction-associated fatty liver disease Linked with obesity and type 2 diabetes
Male sex and older age Most patients are older men

How does it develop?

Researchers are still debating its origin. One idea is that cHCC-CCA arises from liver stem or progenitor cells, which can develop into either liver cells or bile duct cells. Another is that an HCC or iCCA changes its features as it grows. Molecular studies show that both parts of the tumour usually come from the same original cell.

4. How does it look

On scans

Feature Description
Mixed pattern Some areas behave like HCC on contrast scans, others like cholangiocarcinoma
Arterial enhancement Bright areas in the arterial phase, like HCC
Delayed enhancement Gradual filling in, typical of fibrous bile duct cancers
Capsule retraction Pulling in of the liver surface in some cases
Lymph nodes Enlarged nodes near the liver are common

Because the scan appearance is often mixed, cHCC-CCA is easily mistaken for HCC or cholangiocarcinoma before surgery.

Under the microscope

Feature Description
HCC component Sheets and trabeculae of cells resembling liver cells
Cholangiocarcinoma component Glands surrounded by fibrous tissue
Transition zones Areas where the two components blend
Intermediate cell carcinoma A subtype with cells that have features of both types

Special stains

Marker Points towards
HepPar-1, arginase-1, glypican-3 Liver cell differentiation
CK7, CK19, MUC1 Bile duct differentiation
Stem cell markers (such as CD56 or EpCAM) May be present but are not required for diagnosis

5. Symptoms

Early cHCC-CCA often causes no symptoms. Many tumours are found during surveillance scans for people with cirrhosis or chronic hepatitis.

Common symptoms

  • Pain or discomfort in the upper right abdomen
  • Weight loss without trying
  • Loss of appetite and feeling full quickly
  • Tiredness and weakness
  • A lump or swelling under the right ribs

Symptoms of advanced disease or liver failure

Symptom Possible cause
Yellowing of the skin and eyes (jaundice) Blocked bile ducts or liver failure
Swollen abdomen (ascites) Fluid build-up from cirrhosis or tumour
Itching Blocked bile flow
Confusion Liver failure
Bone pain or cough Spread to bone or lungs

When to seek medical advice

See a doctor about persistent pain under the right ribs, unexplained weight loss or yellowing of the skin. People with cirrhosis or chronic hepatitis should attend regular liver surveillance, usually an ultrasound every 6 months.

Liver surveillance for people at risk

Group Recommended surveillance
People with cirrhosis Ultrasound, with or without AFP, every 6 months
People with chronic hepatitis B Regular checks; surveillance depending on age, ethnicity and family history
People treated for liver cancer CT or MRI at intervals set by the team

Surveillance helps find liver cancers at an earlier stage, when surgery or other curative treatments are more likely to be possible.

6. Diagnosis

Test Purpose
Blood tests Liver function, blood count, clotting
Tumour markers AFP and CA 19-9; both raised suggests a mixed tumour
Multiphase CT or MRI Shows the tumour pattern, size, blood vessels and lymph nodes
Biopsy Confirms the diagnosis, though a small sample may show only one component
CT chest Checks for lung spread
Assessment of liver function Child-Pugh score, which guides treatment choices
Molecular testing May find targetable changes such as FGFR2 or IDH1, mainly in the bile duct component

Many cHCC-CCAs are only diagnosed after surgery, when the whole tumour is examined.

Staging

Staging usually follows the TNM system for intrahepatic cholangiocarcinoma:

Stage Description
Stage I A single tumour without blood vessel invasion
Stage II Blood vessel invasion or several tumours
Stage III Spread through the liver surface, to nearby organs or to lymph nodes
Stage IV Spread to distant organs

7. Treatment

Treatment is planned by a liver cancer multidisciplinary team, including hepatobiliary surgeons, hepatologists, oncologists and radiologists.

Surgery

Option Notes
Liver resection Removal of the part of the liver containing the tumour
Lymph node dissection Usually recommended because nodal spread is common
Liver transplant Not standard; considered only in selected cases or trials

Resection with lymph node dissection is currently the only treatment that can cure cHCC-CCA (Beaufrère, Calderaro and Paradis, 2021). It is possible when the tumour is limited and the remaining liver works well enough.

What to expect around liver surgery

Stage What happens
Before Scans to measure the remaining liver; sometimes portal vein embolisation to grow the healthy side
Operation Open or keyhole removal of part of the liver and nearby lymph nodes
After A short stay in high-dependency care, then the ward
Hospital stay Usually 5-10 days
Recovery The liver regrows over several weeks; most people need 6-12 weeks to feel fully recovered
Results Pathology confirms both components, margins and lymph node status

Local treatments

Treatment When used
Ablation Small tumours in people unable to have surgery
Chemoembolisation (TACE) Tumours confined to the liver
Radioembolisation (SIRT) Larger tumours confined to the liver
Stereotactic radiotherapy Selected tumours not suitable for surgery

These treatments are borrowed from HCC care. They may work less well against the bile duct component.

Systemic treatment

Treatment Evidence
Gemcitabine plus cisplatin In 123 patients at one US centre, disease control was better with gemcitabine and a platinum drug than with gemcitabine and 5-FU (Trikalinos et al., 2018)
Chemotherapy versus sorafenib In a European study of 101 patients, survival was not clearly different between chemotherapy and non-chemotherapy treatments (Pomej et al., 2023)
Immunotherapy Some patients respond; durvalumab or pembrolizumab with chemotherapy is often used, following cholangiocarcinoma practice
Targeted drugs For FGFR2 fusions, IDH1 mutations or other changes, when found
Clinical trials Strongly encouraged

In the European cohort, patients were mostly men (69%) with an average age of about 65. Of 7 patients given immune checkpoint inhibitors, 2 had a response (Pomej et al., 2023).

Side effects

Treatment Possible side effects
Liver surgery Pain, bleeding, bile leak, temporary liver failure
TACE or SIRT Pain, fever, nausea, tiredness
Chemotherapy Tiredness, infection risk, nausea, low blood counts
Immunotherapy Inflammation of the bowel, liver, lungs, skin or hormone glands
Kinase inhibitors Hand-foot skin reaction, diarrhoea, high blood pressure

8. Outlook (prognosis)

Factor Effect on outlook
Complete removal Best chance of long-term survival
Lymph node spread Worse outlook
Blood vessel invasion Higher recurrence risk
Underlying cirrhosis Limits treatment options
Advanced disease Treatment aims to control growth and symptoms

Overall, the outlook for cHCC-CCA is worse than for HCC and similar to intrahepatic cholangiocarcinoma (Beaufrère, Calderaro and Paradis, 2021). Recurrence after surgery is common, so close follow-up is needed.

If the cancer comes back

Recurrence is most common within the first two years after surgery, usually inside the liver. Options depend on where it appears and how well the liver works. A single recurrence may be treated with repeat surgery or ablation, while widespread disease is treated with systemic therapy. Palliative care teams help with pain, itching, appetite and emotional support at any stage, not only at the end of life.

9. Follow-up

Follow-up Purpose
CT or MRI every 3-6 months Detects recurrence in the liver or elsewhere
AFP and CA 19-9 Rising levels may signal recurrence
Liver function tests Monitor the remaining liver
Hepatitis treatment Antiviral therapy for hepatitis B or C
Cirrhosis care Varices screening, nutrition and vaccination

10. Living with combined hepatocellular-cholangiocarcinoma

  • Avoid alcohol completely to protect your liver
  • Take antiviral medicines as prescribed if you have hepatitis B or C
  • Eat a balanced diet with enough protein; a dietitian can help if you are losing weight
  • Stay active within your limits
  • Check with your team before taking new medicines, including herbal remedies and painkillers
  • Report jaundice, fever, confusion or swelling promptly
  • Get vaccinated against hepatitis A and B, flu and pneumococcus if your team advises it
  • Keep a symptom diary to share at clinic visits, noting weight, appetite and pain
  • Seek support from liver cancer charities and palliative care teams when needed

11. Frequently asked questions

Question Answer
Is it the same as liver cancer? It is a type of primary liver cancer with mixed features
Why was my diagnosis changed after surgery? Biopsies and scans often show only one part of the tumour
Can I have a liver transplant? Usually not; it is considered only in selected cases
Will hepatitis treatment help? Yes, it protects the liver and may lower the risk of new tumours
Is it inherited? No; it develops because of acquired liver damage and chance changes in cells
Should my family be tested for hepatitis? Yes, close contacts of people with hepatitis B should be tested and vaccinated
Can diet help? Good nutrition supports recovery; limit salt if you have fluid build-up
Are there clinical trials? Yes; ask your team about trials for liver or biliary cancers

12. Questions to ask your care team

  • Can the tumour be removed with surgery?
  • Will my lymph nodes be removed?
  • How well is my liver working?
  • Has the tumour been tested for FGFR2, IDH1 or other targetable changes?
  • Which systemic treatment do you recommend, and why?
  • How often will I have scans and blood tests after treatment?
  • Am I eligible for a clinical trial?
  • Can I be referred to a palliative care or symptom control team?

Resources

  1. Beaufrère, A., Calderaro, J. and Paradis, V. (2021) ‘Combined hepatocellular-cholangiocarcinoma: an update’, Journal of Hepatology, 74(5), pp. 1212-1224.
  2. Brunt, E. et al. (2018) ‘cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation’, Hepatology, 68(1), pp. 113-126.
  3. Pomej, K. et al. (2023) ‘Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma: a European multicenter cohort’, ESMO Open, 8(1), 100783.
  4. Trikalinos, N.A. et al. (2018) ‘Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience’, Journal of the National Comprehensive Cancer Network, 16(10), pp. 1193-1199.
  5. National Cancer Institute (2026) Hepatocellular Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.